




RealRate

PHARMACEUTICAL 2022

Sigilon Therapeutics Inc
Rank 323 of 471

sigilon
therapeutics™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sigilon Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sigilon Therapeutics Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Sigilon Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 56% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	126,394
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,888
Liabilities, Non-Current	26,988
Other Assets	13,981
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	5,333
Other Net Income	-1,675
Other Revenues	9,599
Property and Equipment	3,994
Research and Development	65,069
Selling, General and Administrative Expense	20,166

Output Variable	Value in 1000 USD
Assets	144,369
Liabilities	67,209
Expenses	85,235
Revenues	9,599
Stockholders Equity	77,160
Net Income	-77,311
Comprehensive Net Income	-77,316
BaseVar	154,048
ECR before Limited Liability	86%
Economic Capital Ratio	219%